European Medicine Agency's Pott welcomes criticism of EPARs
This article was originally published in SRA
The European Medicines Agency has said it welcomes criticism of its European public assessment reports following a recent call for an improvement in the way that the agency uses the makes public details about clinical trial results through the reports1,2.
You may also be interested in...
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.